San Francisco—Boughton Soleil, the Chief Legal Officer of Hims & Hers Health, Inc. (NYSE:HIMS), recently executed a series of stock transactions, including selling shares valued at over $1.6 million. The transactions were conducted under a pre-established Rule 10b5-1 trading plan.
Following these transactions, Soleil retains direct ownership of 165,650 shares of Hims & Hers Health. The stock option exercises and subsequent sales were part of a strategic trading plan designed to align with the company's long-term financial goals. With a P/E ratio of 64.29 and earnings per share of $0.47, HIMS demonstrates strong growth potential. With a P/E ratio of 64.29 and earnings per share of $0.47, HIMS demonstrates strong growth potential.
Following these transactions, Soleil retains direct ownership of 165,650 shares of Hims & Hers Health. The stock option exercises and subsequent sales were part of a strategic trading plan designed to align with the company's long-term financial goals.
In other recent news, Hims & Hers Health has been the subject of several significant developments. The company reported a 77% year-over-year increase in Q3 sales, surpassing $400 million, and an adjusted EBITDA over $50 million. Revenue projections for Q4 2024 range between $465 million and $470 million. BofA Securities maintained an Underperform rating on Hims & Hers due to concerns about the future of the company's compounded GLP-1 products. However, the company received a Buy rating from BTIG and was named a top pick for 2025 by Needham & Company due to its robust revenue growth. Morgan Stanley (NYSE:MS) also initiated coverage on Hims & Hers with an Overweight rating. The company's anticipated product launches hinge on the ability to compound these substances, which are now under scrutiny due to recent actions by Novo Nordisk (NYSE:NVO). Lastly, Hims & Hers announced a partnership with Eli Lilly (NYSE:LLY) to streamline access to FDA-approved obesity medication Zepbound.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.